Sbir concept award to novomedix- novel small molecules for the treatment of rhabdomyosarcoma
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91022C00001
- Awardee
-
Novomedix LLC UEI XQYMHKGDMU75
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $355,000
Award facts
- Opportunity
-
- 75091020R00043 Solicitation number
- Contract value 100% obligated
- $355,000.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 47 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- San Diego, CA 92126, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $55,000 | |
| Original award | $300,000 |
About this award
Novomedix LLC, a woman-owned small business, has been awarded a $355,000 firm fixed price contract from the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to perform research and development on novel small molecules for the treatment of rhabdomyosarcoma, a rare cancer affecting muscle tissue. This is a Small Business Innovation Research (SBIR) concept award, which is a set-aside for small businesses. The contract has an ultimate completion date of June 28, 2024. In addition to this federal contract, Novomedix has also received multiple grants from the National Heart, Lung, and Blood Institute (NHLBI) to support research on therapies to mitigate heart toxicity caused by chemotherapy drugs and to develop treatments for diabetic cardiovascular disease.
Quick answers
Who was awarded contract 75N91022C00001?
75N91022C00001 was awarded to Novomedix LLC by National Cancer Institute (National Institutes of Health) on January 19, 2022.
How much is contract 75N91022C00001 worth?
The government has obligated $355,000 on 75N91022C00001.
Was contract 75N91022C00001 competed?
The extent of competition for 75N91022C00001 was full and open competition after exclusion of sources. The government received 47 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award